Board & Leadership Amulet has recently expanded its board with notable healthcare and fertility diagnostics leaders, indicating a strategic focus on governance, credibility, and potential partnerships with health and biotech investors. This presents opportunities to engage with decision makers on collaborations, strategic investments, and guidance for scale.

Series A Momentum The company closed a $6M Series A in August 2024, signaling validation of its technology and growth trajectory. This creates openings for upsell of advanced analytics, enterprise-grade deployments for food manufacturers, and expanded data collaboration or licensing deals.

Two Brand Strategy With Allergy Amulet targeting consumer wearables for allergen detection and Amulet Scientific supplying tech to manufacturers for toxins detection, there are dual pathways for sales outreach: consumer health tech partnerships and B2B sensor/analytic solutions for the food industry.

Public Support & Grants Past NIH and USDA grant support suggests access to government-aligned partnerships and potential funding-backed collaborations. This can facilitate co-development opportunities, pilot programs, and grant-funded projects with larger institutions or corporate partners.

Moderate Revenue, High Growth Potential Current revenue is in the low millions with total funding at $14M, indicating a startup poised for rapid expansion. This environment is conducive to strategic corporate partnerships, early-adopter programs with food manufacturers, and consulting/services engagements to accelerate deployment of Amulet Scientific solutions.